This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TTNP Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Titan Pharmaceuticals Stock (NASDAQ:TTNP) Get Titan Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.55▼$4.8050-Day Range$3.64▼$5.9352-Week Range$3.53▼$5.76Volume3.10 million shsAverage Volume76,658 shsMarket Capitalization$7.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Titan Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics based on its ProNeura long‐term, continuous drug delivery platform. Headquartered in South San Francisco, California, the company seeks to enhance patient outcomes through sustained‐release implants designed to deliver medication over extended periods. Titan’s platform is engineered to maintain consistent drug levels while reducing dosing frequency, with the goal of improving compliance and minimizing side effects often associated with conventional dosing schedules. The company’s lead product, Probuphine®, is a buprenorphine implant approved by the U.S. Food and Drug Administration in 2016 for maintenance treatment of opioid dependence. Probuphine delivers six months of continuous buprenorphine therapy via a small subdermal implant, offering an alternative to daily oral dosages. Titan originally commercialized Probuphine through a partnership with a specialty pharmaceutical company, and it continues to explore strategic collaborations to expand patient access within the United States and potential markets overseas. In addition to its marketed product, Titan maintains a pipeline of development programs aimed at addressing central nervous system disorders. Research efforts include next‐generation implants for migraine prophylaxis and psychiatric indications such as schizophrenia. The company’s leadership team, led by President and Chief Executive Officer Sunil Bhonsle, combines expertise in drug delivery technology and biopharmaceutical development. Titan Pharmaceuticals remains committed to advancing its ProNeura platform to bring long‐acting implant therapies to patients with chronic and complex conditions.AI Generated. May Contain Errors. Read More Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TTNP Stock News HeadlinesTitan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan CorporationOctober 3, 2025 | globenewswire.comTitan Pharmaceuticals Approves Merger with Black TitanAugust 26, 2025 | msn.comApple just sent a powerful signal to investorsApple just crossed a $5 trillion market value as shares climbed 25% this year, fueled by new product launches and rising interest in foldable phones. Mode Mobile is building on top of that ecosystem with its EarnOS platform, already serving 490M+ users across 170+ countries and generating $115M+ in lifetime revenue. Deloitte ranked Mode North America's number 1 fastest-growing software company in 2023 after 32,481% growth. Pre-IPO shares are available at $0.52 before the price changes on August 14.August 4 at 1:00 AM | Mode Mobile (Ad)TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNPAugust 5, 2025 | businesswire.comURGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)July 29, 2025 | globenewswire.comTitan Pharmaceuticals Inc (TTNP) - Investing.comJuly 4, 2025 | investing.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - MorningstarJune 29, 2025 | morningstar.comMTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - NasdaqJune 29, 2025 | nasdaq.comSee More Headlines TTNP Stock Analysis - Frequently Asked Questions How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) released its quarterly earnings data on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter. When did Titan Pharmaceuticals' stock split? Shares of Titan Pharmaceuticals reverse split before market open on Tuesday, January 9th 2024.The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Titan Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings8/14/2025Today8/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TTNP CIK910267 Webwww.titanpharm.com Phone(650) 244-4990Fax650-244-4956Employees10Year Founded1992Profitability EPS (Trailing Twelve Months)($2.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.71 million Net MarginsN/A Pretax MarginN/A Return on Equity-108.60% Return on Assets-95.64% Debt Debt-to-Equity RatioN/A Current Ratio11.60 Quick Ratio11.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book2.22Miscellaneous Outstanding Shares1,330,000Free Float1,320,000Market Cap$7.88 million OptionableOptionable Beta1.37 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:TTNP) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our PartnersA Wall Street Veteran's Weekly Trade for Any Market ConditionDave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
